Fig. 6: Therapeutic effects of LIPPCPO formulas in breast cancer mice.
From: Synthetic vectors for activating the driving axis of ferroptosis
A Schematic illustration of LIPPCPO formula treatment in tumor-bearing mice. After 14 days post-implantation of fLuc-4T1-R cells, each mouse received saline (n = 5 mice), Artesunate (AS) (11.7 mg/kg, n = 5 mice), LIPPCPO (100 mg/kg, n = 5 mice), or AS@LIPPCPO (111.7 mg/kg, n = 5 mice) thrice a week. B Tumor growth curves of each mouse. After receiving the indicated treatments, the tumor volumes of each mouse were recorded every 3 days and displayed as tumor growth kinetics. C Bioluminescence images of tumor-bearing mice. Animals receiving different treatments were subjected to bioluminescence imaging (BLI) using an IVIS imaging spectrum system at 0, 7, 14, 21, and 28 days. D Ex vivo imaging of pulmonary metastases. Tumor-bearing mice receiving different treatments were sacrificed on the 28th day for visualization of metastatic foci in the lungs. BF: bright field, BLI: bioluminescence imaging. E Kaplan–Meier curves displaying the survival rates of treated tumor-bearing mice over 60 days. Source data are provided as a Source Data file.
